The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer

Inclusion Criteria:

* Adenocarcinoma of the prostate with radiographic evidence of metastatic disease.
* Willingness to undergo a baseline tumor biopsy.
* Castrate levels of testosterone (testosterone \< 50 ng/dL) on androgen deprivation therapy (ADT) with evidence of progression on ADT. GnRH therapy will be continued for those on it at baseline
* Patient must have suspected tumor in an area that is safe to biopsy.
* Other prior hormonal interventions or experimental approaches are allowed. These therapies must have been discontinued for a minimum of 28 days with cancer progression.
* Prior or concurrent use of bisphosphonates is allowed.
* One prior non-taxane chemotherapy allowed
* ≥ 3 weeks since major surgery; ≥ 4 weeks since radiotherapy; ≥ 8 weeks since prior strontium-89 or samarium 153
* Performance Status: ECOG 0 or 1
* ANC \> 1,500/\_l; platelets \> 100,000/\_l; total Bilirubin \< upper limit of normal; AST and ALT \< 3 x upper limits of normal; creatinine \< 1.5 x upper limits of normal; total fasting cholesterol \< 350 mg/dl; total triglycerides \< 300 mg/dl

Exclusion Criteria:

* Ongoing oral steroid use. Patients with a history of oral steroid use are eligible as long as the steroids have been discontinued prior to study entry. Ongoing topical and/or inhaled steroid use is allowed.
* Prior taxane chemotherapy
* Prior mTOR inhibitors (RAD001, rapamycin, CCI-779)
* Currently active second malignancy other than non-melanoma skin cancer.
* Ongoing peripheral neuropathy of Grade 2